Connection

Eric Meissner to Viral Load

This is a "connection" page, showing publications Eric Meissner has written about Viral Load.
Connection Strength

0.781
  1. IFNL4 Genotype Does Not Associate with CD4 T-Cell Recovery in People Living with Human Immunodeficiency Virus. AIDS Res Hum Retroviruses. 2021 03; 37(3):184-188.
    View in: PubMed
    Score: 0.170
  2. Association of Substance Use With Hospitalization and Virologic Suppression in a Southern Academic HIV Clinic. Am J Med Sci. 2018 06; 355(6):553-558.
    View in: PubMed
    Score: 0.141
  3. Modeling HCV cure after an ultra-short duration of therapy with direct acting agents. Antiviral Res. 2017 08; 144:281-285.
    View in: PubMed
    Score: 0.135
  4. Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy. PLoS One. 2015; 10(7):e0133236.
    View in: PubMed
    Score: 0.118
  5. Prevention of cardiovascular disease for historically marginalized racial and ethnic groups living with HIV: A narrative review of the literature. Prog Cardiovasc Dis. 2020 Mar - Apr; 63(2):142-148.
    View in: PubMed
    Score: 0.040
  6. IFN-?4 Attenuates Antiviral Responses by Enhancing Negative Regulation of IFN Signaling. J Immunol. 2017 12 01; 199(11):3808-3820.
    View in: PubMed
    Score: 0.034
  7. Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial. Ann Intern Med. 2015 Dec 15; 163(12):899-907.
    View in: PubMed
    Score: 0.030
  8. Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin. J Antimicrob Chemother. 2015 Aug; 70(8):2322-9.
    View in: PubMed
    Score: 0.029
  9. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015 Mar 24-31; 313(12):1232-9.
    View in: PubMed
    Score: 0.029
  10. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet. 2015 Mar 21; 385(9973):1107-13.
    View in: PubMed
    Score: 0.028
  11. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA. 2013 Aug 28; 310(8):804-11.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.